KIF6: A Potential Drug Target and Biomarker for Cancer (G221458)

Target Name: KIF6

NCBI ID: G221458

KIF6

KIF6: A Potential Drug Target and Biomarker for Cancer

KIF6, also known as KIF6 variant 1, is a protein that is expressed in various tissues throughout the body, including the brain, heart, and lungs. It is a member of the Kallikrein-related peptidases (KAPs) family, which includes a variety of structurally similar proteins that play important roles in various physiological processes.

One of the unique features of KIF6 is its ability to induce cell death, both in cancer cells and normal cells, through a process called apoptosis. This process is regulated by a variety of factors, including the production of pro-inflammatory cytokines.

KIF6 has also been shown to play a role in the regulation of cell proliferation, and has been shown to inhibit the activity of the oncogene transforming growth factor (TGF-β). This suggests that KIF6 may have potential as a drug target for the treatment of cancer.

In addition to its potential as a drug target, KIF6 has also been shown to be a potential biomarker for several types of cancer, including breast, ovarian, and colorectal cancers. This is because it is often overexpressed in these types of cancer, and can be used as a marker for the disease.

Overall, KIF6 is a protein that has significant potential as a drug target and biomarker, and is being actively targeted by researchers to study its role in various physiological processes. Further research is needed to fully understand the effects of KIF6 on cancer cell growth and the use of KIF6 as a drug.

Protein Name: Kinesin Family Member 6

The "KIF6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KIF6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets